key: cord-0740241-ut4ao2nh
authors: Gammeltoft, Karen A.; Zhou, Yuyong; Galli, Andrea; Offersgaard, Anna; Pham, Long V.; Fahnøe, Ulrik; Feng, Shan; Ramirez, Santseharay; Bukh, Jens; Gottwein, Judith M.
title: Hepatitis C Virus Protease Inhibitors Show Differential Efficacy and Interactions with Remdesivir for Treatment of SARS-CoV-2 in Vitro
date: 2020-12-02
journal: bioRxiv
DOI: 10.1101/2020.12.02.408112
sha: c921b984610d5550a05fb19358ed432b677f79b6
doc_id: 740241
cord_uid: ut4ao2nh

Antivirals targeting SARS-CoV-2 could improve treatment of COVID-19. We evaluated the efficacy of clinically relevant hepatitis C virus (HCV) NS3 protease inhibitors (PI) against SARS-CoV-2 and their interactions with remdesivir, the only antiviral approved for treatment of COVID-19. HCV PI showed differential potency in VeroE6 cell-based antiviral assays based on detection of the SARS-CoV-2 Spike protein. Linear PI boceprevir, telaprevir and narlaprevir had 50% effective concentrations (EC50) of ~40 μM. Among macrocyclic PI simeprevir, paritaprevir, grazoprevir, glecaprevir, voxilaprevir, vaniprevir, danoprevir and deldeprevir, simeprevir had the highest (EC50 15 μM) and glecaprevir the lowest (EC50 >178 μM) potency. Acyclic PI asunaprevir and faldaprevir had EC50 of 72 and 23 μM, respectively. ACH-806, an HCV NS3 protease co-factor NS4A inhibitor, had EC50 of 46 μM. For selected PI, potency was similar in human hepatoma Huh7.5 cells. Selectivity indexes, based on antiviral and cell viability assays, were highest for linear PI. In combination with remdesivir, linear PI boceprevir and narlaprevir showed antagonism, while macrocyclic PI simeprevir, paritaprevir and grazoprevir showed synergism with drug reduction indexes of up to 27 for simeprevir. Treatment of infected cultures with equipotent concentrations (1-fold EC50) of HCV PI revealed minor differences in barrier to SARS-CoV-2 escape. Complete viral suppression was achieved treating with ≥3-fold EC50 boceprevir or combination of 1-fold EC50 simeprevir with 0.4-fold EC50 remdesivir, not leading to significant viral suppression in single treatments. Considering potency, human plasma concentrations and synergism with remdesivir, simeprevir seemed the most promising compound for optimization of future antiviral treatments of COVID-19.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a positive-sense single-stranded RNA virus of the Coronaviridae family, which emerged in humans in 2019 most likely originating from a bat-borne virus. 1-3 SARS-CoV-2 causes coronavirus disease 2019 (COVID-19), a multisystemic disease with initial symptoms mostly localizing to the respiratory tract. Until the end of November 2020, the COVID-19 pandemic has been responsible for >60 million infected, >1.4 million deaths, and an unknown number of individuals suffering from long-term health effects. [4] [5] [6] [7] [8] Repurposing of drugs approved for other medical indications is promoted as a time-saving approach to identification of urgently needed treatments. At present, the only drug approved for treatment of COVID-19 that directly targets SARS-CoV-2 proteins is remdesivir, an inhibitor of the viral nonstructural protein (nsp) 12 polymerase, originally being an investigational broad-spectrum antiviral previously evaluated for treatment of chronic hepatitis C virus (HCV) infection and ebola infection. 9 Another important target of antiviral drugs are viral proteases, which are essential for cleavage of viral polyproteins into functional proteins. [10] [11] [12] The coronavirus main protease (M pro ) or 3 chymotrypsin-like protease (3CLpro) is a cysteine protease corresponding to nsp5. M pro mediates 11 cleavage events at conserved sites of the polyprotein and is thus essential for viral replication. [13] [14] [15] In addition, M pro has no cellular homologues and is highly conserved between different coronaviruses, making it an interesting drug target. 16 Hepatitis C virus is a positive-sense single-stranded RNA virus of the Flaviviridae family, which was classified into 8 major genotypes and various subtypes. 17, 18 The main HCV protease, nonstructural protein 3 (NS3), is a chymotrypsin-like serine protease. [19] [20] [21] Together with its essential co-factor, NS4A, it mediates 4 cleavage events of the polyprotein. Inhibitors of this protease are important components of recently developed highly efficient HCV treatment regimens based on combination of antivirals directly targeting HCV proteins. 22 Initially developed HCV protease inhibitors (PI) showed a linear structure and included boceprevir and telaprevir, which were approved in 2011 in the U.S. and EU, as well as narlaprevir, approved in Table 1 ). Subsequently, PI with macrocyclic structure, including simeprevir, paritaprevir, grazoprevir, glecaprevir, voxilaprevir, vaniprevir, danoprevir and deldeprevir were developed.

These macrocyclic PI were approved between 2013 and 2019 in the U.S., EU or China, with exception of vaniprevir, only approved in Japan and deldeprevir, which was never approved. Of the 4 2 acyclic PI, asunaprevir and faldaprevir, asunaprevir was approved in Japan, Canada and China, while faldaprevir was not approved. Several of the initially developed PI were subsequently discontinued due to the development of more efficient PI with increased activity against the different HCV genotypes (Supplementary Table 1 ). At present clinical use in the U.S., Europe and China is focused on inhibitor combinations, including grazoprevir, glecaprevir and voxilaprevir.

Additionally, in China, inhibitor combinations including paritaprevir, danoprevir or asunaprevir are used in the clinic.

While an inhibitor of HCV NS4A (ACH-806) was tested in clinical phase 1 trials, development was halted due to reversible nephrotoxicity. 23, 24 In this study we investigated in vitro efficacy of a panel of HCV PI, including all clinically approved compounds and selected compounds tested in clinical studies, against SARS-CoV-2. We further evaluated efficacy of an HCV NS4A inhibitor. In concentration-response antiviral assays we determined 50% effective concentrations (EC50), 50% cytotoxic concentrations (CC50) and selectivity indexes (SI). Moreover, we evaluated interactions with remdesivir for selected linear and macrocyclic compounds. Finally, in longer-term cultures we evaluated selected inhibitors for their barrier to viral escape.

To determine the potency of a panel of HCV PI and an HCV NS4A inhibitor against SARS-CoV-2, we developed a cell-based antiviral assay in 96well plates, adapting an assay previously developed to determine potency of HCV PI against HCV. [24] [25] [26] [27] [28] [29] [30] [31] First, concentration response studies were carried out in VeroE6 cells using inhibitor concentrations not resulting in reduction of cell viability (relative cell viability >90%). All tested inhibitors were able to inhibit the virus with EC50 values in the micromolar range, with exception of glecaprevir, voxilaprevir and deldeprevir, where EC50 values could not be determined due to cytotoxicity of the drugs or antiviral activity of the diluent dimethyl sulfoxide (DMSO) at high drug concentrations ( Figure 1 , Table 1 , Supplementary Figure 2 To confirm potency of the tested PI in human cells, selected PI were studied in similar assays in human hepatoma Huh7.5 cells. In these assays, boceprevir, simeprevir and grazoprevir showed similar concentration response curves and EC50 values as in VeroE6 cells ( Figure 2 , Table 1 Based on these assays, the linear inhibitors had the highest selectivity indexes (SI=CC50/EC50), >27.6 for boceprevir, >10.8 for telaprevir and 7.3 for narlaprevir (Table 1) . Of the macrocyclic inhibitors, paritaprevir and grazoprevir had the highest SI (5.6 and 5.7, respectively), while simeprevir and vaniprevir had slightly lower SI of 3.9 and 3.4, respectively. For glecaprevir, voxilaprevir, danoprevir, and deldeprevir SI could not be determined. For the acyclic inhibitors, SI values were 6.3 for faldaprevir and 3.7 for asunaprevir. Finally, SI values calculated based on assays in Huh7.5 cells were comparable to those based on assays in VeroE6 cells (Table 1) .

For the HCV NS4A inhibitor ACH-806, in VeroE6 cells EC50 was 46 µM, CC50 was >429 µM and SI was >9.3 ( Figure 1 , Table 1 , Supplementary Figure 3 ). HCV PI showed differential interactions with remdesivir. To study interactions between selected PI and remdesivir, 96-well based synergy assays were carried out using the method of Chou and Talalay 32,33 , as described in Materials and Methods, and as previously applied for studies on HCV. 26 infection. On day 7, in narlaprevir and faldaprevir treated cultures 60% of culture cells were infected; these cultures were closed on day 9 due to massive cell death.

As suboptimal viral suppression was observed under treatment with 1-fold EC50, we chose the PI with the highest SI to enable longer-term treatment at higher fold EC50 concentrations. VeroE6 cells infected with SARS-CoV-2 were treated with 1-, 1.5-, 2-, 2.5, 3-and 5-fold EC50 of boceprevir ( Figure 6 ). Treatment with 1-and 1.5-fold EC50 of boceprevir only had a minor impact on viral spread on day 1 post infection and treatment initiation, while 90% of culture cells became infected on day 3, as observed for nontreated control cells. Also, in cultures treated with 2 and 2.5-fold EC50, 90% of culture cells became infected on day 5. In contrast, treatment with 3-and 5-fold EC50 resulted in sustained viral suppression with no evidence of infected cells in the culture treated with 3-fold EC50 from day 3 and in the culture treated with 5-fold EC50 from day 1 during a follow up period of 7 and 17 days, respectively. In addition, from cultures treated with 3-and 5-fold EC50 on day 5 and day 3, respectively, replicate cultures receiving no treatment were derived, which did not show any infected cells during a follow up period of 10 days, suggesting that the infection was cured under these treatments.

To further study and confirm the interactions of PI with remdesivir, 2 PI with apparent differential interactions with remdesivir were selected for longer-term treatment of SARS-CoV-2. VeroE6 cells infected with SARS-CoV-2 were treated with the PI boceprevir or simeprevir singly, remdesivir singly or either PI in combination with remdesivir. Inhibitor concentrations were selected to confer suboptimal effects in order to rule out viral suppression by treatment with single inhibitors.

Equipotent concentrations of PI were used based on data shown in Figures 1 and 5 . For remdesivir, potency was evaluated based on concentration response curves obtained from data shown in Figure   3 and Supplementary Figure 5 , and in addition based on pilot longer-term treatment assays (data not shown). Treatment with remdesivir, boceprevir or simeprevir singly as well as treatment with boceprevir + remdesivir had none or only a minor impact on viral spread on day 1 post infection and treatment initiation, while 80 to 90% of culture cells became infected on day 3, as observed for nontreated control cells (Figure 7 ). In contrast, in cultures treated with simeprevir + remdesivir complete and sustained viral suppression was achieved with no evidence of infection from day 1 during a follow up period of 15 days. In addition, to confirm complete viral suppression, from this culture a replicate culture receiving no treatment was derived on day 5, which did not show any infected cells during a follow up period of 19 days.

We provided a head-to-head comparison of the efficacy of a panel of clinically relevant HCV PI, including all approved PI, against SARS-CoV-2 in cell-based assays. In short-term antiviral assays, PI showed differential potency with EC50 values between 15 µM (simeprevir) and >178 µM (glecaprevir). Detailed short-term synergy studies with a PI sub-panel revealed PI structure dependent interactions with remdesivir, with linear inhibitors showing antagonism and macrocyclic inhibitors showing synergism. In longer-term cultures, at relatively low equipotent concentrations PI showed small differences regarding barrier to escape. For boceprevir, a relatively high SI facilitated treatment with higher concentrations revealing its potential to completely suppress viral infection. Further, combination of simeprevir and remdesivir suppressed viral infection at relatively low inhibitor concentrations, shown to be subtherapeutic in single treatments.

EC50 against SARS-CoV-2 were in the micromolar range, with the lowest EC50 (15 µM for simeprevir) approaching EC50 of remdesivir, determined to be 2.5 µM in this study, which was in line with previously reported results. 34, 35 However, EC50 of PI against SARS-CoV-2 were higher than EC50 against HCV: Initially developed HCV PI such as boceprevir and simeprevir were ̴ 10to 1,000-fold less potent, while optimized HCV PI such as grazoprevir, glecaprevir and voxilaprevir were ̴ 1,000-to 100,000-fold less potent against SARS-CoV-2 than against different HCV isolates. 24, [26] [27] [28] 30, [36] [37] [38] Boceprevir showed the highest SI of >27.6, while simeprevir showed one of the lowest SI of 3.9. Of note, some clinically relevant drugs such as digoxin have low therapeutic breadth with SI as low as 2, 39 and simeprevir has proven safe in clinical practice. However, to estimate the clinical potential of inhibitors, comparison of their EC50 with clinically achievable plasma and tissue concentrations is more relevant than comparison with in vitro CC50 values. For most HCV PI, peak plasma concentrations (Cmax) were significantly lower than the determined EC50 values (Supplementary Table 2 ). The most favorable Cmax/EC50 ratio was found for simeprevir (Cmax/EC50 of ~1), followed by faldaprevir (Cmax/EC50 of ~0.2), as well as boceprevir, telaprevir and vaniprevir (Cmax/EC50 of ~0.1). For HCV PI detailed information on liver concentrations is available and in general these are higher than plasma concentrations: For faldaprevir, boceprevir, telaprevir and vaniprevir liver concentrations are ~32-, ~30-, ~35-, and 20to 280-fold higher than plasma concentrations, and thus ~6-, ~2.3-. 4.6-, and up to 36-fold higher than EC50 values, respectively. 31, 40, 41 For simeprevir, liver concentrations are 20-to 40-fold higher than plasma concentrations and thus up to 39-fold higher than EC50 values. 42 In rats, following a single oral administration of simeprevir, concentrations in the intestine, which is permissive to SARS-CoV-2 infection, 43 were up to 128-fold higher than in the plasma, while concentrations in other tissues were roughly equal to plasma concentrations. 44 To further estimate the clinical potential of simeprevir for treatment of SARS-CoV-2 it would be relevant to determine concentrations in relevant tissues such as in the lungs and the kidneys in humans following multiple doses in steady state. 45 At clinically achievable tissue concentrations, inhibitor efficacy can be improved by combination treatments with synergistic and thus drug saving effects as reported here for the macrocyclic PI simeprevir, paritaprevir and grazoprevir in combination with remdesivir and as recently suggested short-term assays based on determination of cytopathic effects. 47 However, our extensive results in short-term assays based on detection of viral protein followed by application of a highly relevant method for synergy evaluation, clearly demonstrated that the mode of interaction between PI and remdesivir depended on the PI structure. Thus, the linear PI boceprevir and narlaprevir showed mostly antagonism, while macrocyclic PI mostly showed synergism with up to 27-fold drug reduction effects for simeprevir. We confirmed these PI structure dependent interactions with remdesivir in a longer-term treatment assay where combination of boceprevir with remdesivir did not result in additive or synergistic effects, while for combination of simeprevir and remdesivir synergistic effects were observed. This structure dependence remains to be explained, however, it could be caused by differential cellular uptake or metabolization. Further, simeprevir might target the SARS-CoV-2 polymerase in addition to M pro , potentially by a different mechanism than remdesivir, which might explain the observed synergy. 46 Finally, PI were suggested to affect innate immunity, as well as alternative viral targets, which could provide the basis for the observed differences in interactions with remdesivir. While remdesivir is the only antiviral directly targeting SARS-CoV-2 that is approved for treatment of patients with COVID-19, its clinical efficacy has recently been questioned. 9,69-73 Relatively limited clinical efficacy compared to high in vitro efficacy of remdesivir 34,35 might be due to its poor distribution to the lungs. 45 Improving drug formulation including development of inhalable formulations and combination with simeprevir might have the potential to increase clinical efficacy of remdesivir.

While carrying out this study, several research articles addressing a potential effect of HCV PI on SARS-CoV-2 were published. Using in silico modelling approaches, at least 21 studies predicted 12 binding of different HCV PI to SARS-CoV-2 M pro . [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] [62] [63] [64] [65] [66] [67] [68] 74 In several of these studies HCV PI were identified as top candidates following screening of large drug libraries, however, some of these studies also yielded contradictory results. Of these studies, 10 identified simeprevir 50 48 HCV PI were designed and optimized to bind the HCV NS3 protease. In modelling studies, 3D similarity between the HCV NS3 protease and SARS-CoV-2 M pro were reported 48,60 even though sequence homology is low. While both viral proteases are chymotrypsin like proteases, the HCV NS3 protease has a larger and more shallow binding groove. 59 Boceprevir was confirmed to target M pro , as it inhibited M pro in enzymatic assays 59, 76 and the M pro -boceprevir crystal structure was solved. 59, 77 Simeprevir also inhibited M pro in enzymatic assays 46,76 , however, with relatively low efficacy. 46,59 Based on this finding, Lo et al. investigated alternative targets and found simeprevir to also inhibit the SARS-CoV-2 polymerase in enzymatic assays. 46 Thus, simeprevir might have a dual mechanism of action. It should be noted that simeprevir was also described to impact cellular innate immune responses 61 and that alternative viral targets, including nsp3 (papain like protease domain), nsp12 (polymerase), nsp13 (helicase), nsp14 (exonuclease and methyltransferase), nsp15 (endoribonuclease), nsp16 (2'-o-ribose methyltransferase), as well as structural proteins N (capsid) and Spike, were suggested for paritaprevir, grazoprevir and simeprevir by modelling studies. 53, 67, [78] [79] [80] [81] [82] Future detailed molecular studies are required to fully define the viral targets of different HCV 13 PI.

Finally, we report antiviral activity of the HCV NS4A inhibitor ACH-806. Future studies are required to define the SARS-CoV-2 target of this compound and to investigate its potential to inform design of SARS-CoV-2 inhibitors.

In conclusion, following initial partially contradictory reports suggesting efficacy of selected HCV PI against SARS-CoV-2, we here provide a head-to-head comparison of the efficacy of a panel of clinically relevant HCV PI against SARS-CoV-2, including detailed studies of interaction with remdesivir. Given its favorable potency, its comparatively high human plasma and tissue concentrations, and its observed synergy with remdesivir, simeprevir might be a lead candidate for design of optimized coronavirus inhibitors and might have direct clinical relevance. Analyzer (CTL Europe GmbH, Bonn, Germany). 84 The mean of counts from noninfected and nontreated wells, which was usually <50, was subtracted from counts of infected wells. Counts from infected and treated wells were related to the mean count of the 14-replicate infected nontreated wells to calculate % residual infectivity; mean counts of infected nontreated wells were 3,000-4,000 for VeroE6 cells and 1,000-2,000 for Huh7.5 cells. Datapoints are given as means of 7 replicates with SEM. Sigmoidal concentration response curves were fitted and EC50 values calculated as described previously using Graphpad Prism 8.0.0 with a bottom constraint of 0 applying the formula Y= Top/(1+10 (Log10EC50-X)*HillSlope ). 31, 85 Representative images from concentration-response antiviral treatment assays are shown by Gilmore, Zhou et al. 86 16 Analysis of interactions of PI and remdesivir. Synergy versus antagonism of selected PI in combination with remdesivir for inhibition of SARS-CoV-2 was investigated using the method of Chou and Talalay 33 and CompuSyn freeware (ComboSyn Inc.) 32 based on protocols previously established for HCV. 26 The experimental setup was similar to that of the concentration-response antiviral treatment assays described above. In brief, VeroE6 cells were seeded at 10,000 cells per well in 96-well flat-bottom plates, medium was changed to 50 µL fresh medium, and cells were inoculated with SARS-CoV-2/human/Denmark/DK-AHH1/2020 at MOI 0.0016 by adding 50 µL virus stock diluted in medium to each well. Following 1-hour incubation at 37°C and 5% CO2, 

A pneumonia outbreak associated with a new coronavirus of probable bat origin

A novel coronavirus from patients with pneumonia in China

A new coronavirus associated with human respiratory disease in China

Clinical Characteristics of Patients Who Died of Coronavirus Disease 2019 in China

Clinical characteristics of coronavirus disease 2019 in China

Unique epidemiological and clinical features of the emerging 2019 novel coronavirus pneumonia (COVID-19) implicate special control measures

World Health Organization. WHO Coronavirus Disease (COVID-19)

Remdesivir for the Treatment of Covid-19 -Final Report

Proteases and protease inhibitors in infectious diseases

Understanding the hepatitis C virus life cycle paves the way for highly effective therapies

The molecular and structural basis of advanced 21

antiviral therapy for hepatitis C virus infection

Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors

Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors

Designing of improved drugs for COVID-19: Crystal structure of SARS-CoV-2 main protease Mpro

Design and Evaluation of Anti-SARS-Coronavirus Agents Based on Molecular Interactions with the Viral Protease

Expanded Classification of Hepatitis C Virus Into 7 Genotypes and 67 Subtypes: Updated Criteria and Genotype Assignment Web Resource

Identification of a novel hepatitis C virus genotype from Punjab, India: Expanding classification of hepatitis C virus into 8 genotypes

Crystal structure of the hepatitis C virus NS3 protease domain complexed with a synthetic NS4A cofactor peptide

NS3-4A of hepatitis C virus is a chymotrypsin-like protease

Nonstructural protein 3-4A: The Swiss army knife of hepatitis C virus

Hepatitis C Virus Resistance to Direct-Acting Antiviral Drugs in Interferon-Free Regimens

Short-term antiviral activity and safety of ACH-806(GS-9132), an NS4A antagonist, in HCV genotype 1 infected individuals

Adapted J6/JFH1-based hepatitis C virus recombinants with genotype-22

specific NS4A show similar efficacies against lead protease inhibitors, alpha interferon, and a putative NS4A inhibitor

Differential sensitivity of 5′UTR-NS5A recombinants of hepatitis C virus genotypes 1-6 to protease and NS5A inhibitors

Combination treatment with hepatitis C virus protease and NS5A inhibitors is effective against recombinant genotype 1a, 2a, and 3a viruses

Substitutions at Hepatitis C Virus Genotypes 2-6 NS3 Residues 155, 156, or 168 Induce Complex Patterns of Protease Inhibitor Resistance

Hepatitis C Virus Genotype 1 to 6 Protease Inhibitor Escape Variants:In Vitro Selection, Fitness, and Resistance Patterns in the Context of the Infectious Viral Life Cycle

HCV genotype 1-6 NS3 residue 80 substitutions impact protease inhibitor activity and promote viral escape

Evolutionary Pathways to Persistence of Highly Fit and Resistant Hepatitis C Virus Protease Inhibitor Escape Variants

Differential efficacy of protease inhibitors against HCV genotypes 2a, 3a, 5a, and 6a NS3/4A protease recombinant viruses

CompuSyn software for drug combinations and for general doseeffect analysis, and user's guide

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

Efficient culture of SARS-CoV-2 in human hepatoma cells enhances viability of the virus in human lung cancer cell lines permitting the screening of antiviral compounds

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro

Highly efficient infectious cell culture of three hepatitis C virus genotype 2b strains and sensitivity to lead protease, nonstructural protein 5A, and polymerase inhibitors

Development of an Intergenotypic Hepatitis C Virus (HCV) Cell Culture Method To Assess Antiviral Susceptibilities and Resistance Development of HCV NS3 Protease Genes from HCV Genotypes 1 to 6

Genotype differences in susceptibility and resistance development of hepatitis C virus to protease inhibitors telaprevir (VX-950) and danoprevir

Drug therapy in dental practice: general principles. Part 2 -pharmacodynamic considerations

Bridging in vitro and in vivo metabolism and transport of faldaprevir in human using a novel cocultured human hepatocyte system, hepatopac

Liver-to-plasma vaniprevir (MK-7009) concentration ratios in HCVinfected patients

Center for drug evaluation and research, C. P. and biopharmaceuticals review (S). Application number: 205123Orig1s000. Food Drug Adm

Virological assessment of hospitalized patients with COVID-2019

In vitro activity and preclinical profile of TMC435350, a potent hepatitis C virus protease inhibitor

Tissue distributions of antiviral drugs affect their capabilities of reducing viral loads in COVID-19 treatment

Simeprevir suppresses SARS-CoV-2 replication and synergizes with remdesivir

Boceprevir, calpain inhibitors II and XII, and GC-376 have broad-spectrum antiviral activity against coronaviruses in cell culture

In silico evaluation of the effectivity of approved protease Inhibitors against the main protease of the novel SARS-CoV-2 virus

Targeting SARS-CoV-2: a systematic drug repurposing approach to identify promising inhibitors against 3C-like proteinase and 2′-O-ribose methyltransferase

Virtual screening, molecular dynamics and structure-activity relationship studies to identify potent approved drugs for Covid-19 treatment

Molecular Docking and Virtual Screening based prediction of drugs for COVID-19

Identification of potential inhibitors of three key enzymes of SARS-CoV2 using computational approach

Whole Genome Analysis and Targeted Drug Discovery Using Computational Methods and High Throughput Screening Tools for Emerged Novel Coronavirus (2019-nCoV)

Discovery of Potent SARS-CoV-2 Inhibitors from Approved Antiviral Drugs via Docking Screening

Structure-based virtual screening of phytochemicals and repurposing of FDA approved antiviral drugs unravels lead molecules as potential inhibitors of coronavirus 3C-like protease 25 enzyme

Glecaprevir and Maraviroc are high-affinity inhibitors of SARS-CoV-2 main protease: Possible implication in COVID-19 therapy

Identification of 14 known drugs as inhibitors of the main protease of SARS-CoV-2

Repurposing simeprevir, calpain inhibitor IV and a cathepsin F inhibitor against SARS-CoV-2 and insights into their interactions with Mpro

Both Boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease

Molecular investigation of SARS-COV-2 proteins and their interactions with antiviral drugs

Antiviral effects of simeprevir on multiple viruses

Anti-HCV and anti-malaria agent, potential candidates to repurpose for coronavirus infection: Virtual screening, molecular docking, and molecular dynamics simulation study

Comparative docking of SARS-CoV-2 receptors antagonists from repurposing drugs

Inhibition of SARS-CoV-2 main protease 3CLpro by means of α-ketoamide and pyridone-containing pharmaceuticals using in silico molecular docking

Destabilizing the structural integrity of COVID-19 by caulerpin and its derivatives along with some antiviral drugs: An in silico approaches for a combination 26 therapy

Pharmacoinformatics and molecular dynamics simulation studies reveal potential covalent and FDA-approved inhibitors of SARS-CoV-2 main protease 3CLpro

Investigating the binding affinity, interaction, and structure-activityrelationship of 76 prescription antiviral drugs targeting RdRp and Mpro of SARS-CoV-2

Network analysis, sequence and structure dynamics of key proteins of coronavirus and human host, and molecular docking of selected phytochemicals of nine medicinal plants

Repurposed antiviral drugs for COVID-19 -interim WHO SOLIDARITY trial results

Covid-19: Remdesivir has little or no impact on survival, WHO trial shows

Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial

Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients with Moderate COVID-19: A Randomized Clinical Trial

The place for remdesivir in COVID-19 treatment

Rational approach toward COVID-19 main protease inhibitors via molecular docking, molecular dynamics simulation and free energy calculation

A nanoluciferase SARS-CoV-2 for rapid neutralization testing and screening of anti-infective drugs for COVID-19

GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease

Malleability of the SARS-CoV-2 3CL Mpro Active-Site Cavity Facilitates Binding of Clinical Antivirals

In silico structure modelling of SARS-CoV-2 Nsp13 helicase and Nsp14 and repurposing of FDA approved antiviral drugs as dual inhibitors

Identification of potential inhibitors against SARS-CoV-2 by targeting proteins responsible for envelope formation and virion assembly using docking based virtual screening, and pharmacokinetics approaches

Identification of promising antiviral drug candidates against non-structural protein 15 (NSP15) from SARS-CoV-2: an in silico assisted drug-repurposing study

Identification of novel compounds against three targets of SARS CoV-2 coronavirus by combined virtual screening and supervised machine learning

An integrated drug repurposing strategy for the rapid identification of potential SARS-CoV-2 viral inhibitors

Highly Permissive Cell Lines for Subgenomic and Genomic Hepatitis C Virus RNA Replication

Novel Infectious cDNA Clones of Hepatitis C Virus Genotype 3a (Strain S52) and 4a (Strain ED43): Genetic Analyses and In Vivo Pathogenesis Studies

Recombinant HCV variants with NS5A from genotypes 1-7 have different sensitivities to an NS5A inhibitor but not interferon-α

In vitro efficacy of Artemisinin-based treatments against SARS-CoV-2

Conflict of Interest: none.

 Tables   Table 1 

a EC50, 50% effective concentration (µM), determined in antiviral treatment assays as described in Materials and Methods. For voxilaprevir and deldeprevir, in VeroE6 cells, >50% residual infectivity was observed at the highest noncytotoxic concentrations; for glecaprevir, the highest applied concentration was limited due to antiviral effects of the diluent DMSO; thus, for these PI no precise EC50 value could be determined. EC50 values are also included in Figures 1 and 2